Sign in
Active, not recruitingPhase 2/3

Human Milk Fortification in Extremely Preterm Infants

Key facts

Who runs it
Thomas Abrahamsson, MD, PhD
Where
Sweden5 sites in 1 countryChoose a country to see its sites
Trial code
Status
Active, not recruiting
Phase
Phase 2/3
People taking part
229 people enrolled
Started
1 Feb 2019
Expected to end
31 Jan 2029
Type of study
Interventional, 2 groupsOne group gets an existing treatment, for comparison.
Treatments tested
  • H2MF
  • Bovine milk-based fortifier
Record updated
23 July 2024

Who can take part

Sex
Women and men
Healthy volunteers
Cannot take part
Show the full registry criteria (11)Hide the full registry criteria

Who can take part

  • Gestational age at birth 22+0-27+6: based on prenatal ultrasonography
  • Enteral feeds < 100 mL/kg/day at the day of randomisation
  • Written informed consent from the legal guardians of the infant
  • The home clinic of the infant has the logistics of maintaining the intervention until gestational week 34+0

Who cannot take part

  • Abdominal surgery before the time of inclusion
  • Infants having nutrient fortifier or formula prior to randomisation
  • Lethal or complicated malformation known at the time of inclusion
  • Chromosomal anomalies known at the time of inclusion
  • No realistic hope for survival at the time of inclusion
  • Gastrointestinal malformation known at the time of inclusion
  • Participation in another intervention trial aiming at having an effect on growth, nutrition, feeding intolerance or severe complications such as NEC and sepsis

Where is this trial?

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

This is a randomised controlled multi-centre trial comparing the effect of diet supplementation of a human breast milk-based nutrient fortifier (H2MF®) with standard bovine protein-based nutrient fortifier in 222 extremely preterm infants (born before gestational week 28+0) exclusively fed with human breast milk (own mother´s milk and/or donor milk). The infants will be randomised to receive either the human breast-milk based H2MF® or the standard bovine protein-based nutrient fortifier when oral feeds have reached <100 ml/kg/day.

Read full original descriptionShow less

The randomised intervention, stratified by centre, will continue until the target gestational week 34+0. The infant must not be fed with formula during the intervention period. The allocation will be concealed before inclusion, but after randomisation the study is not blinded.

Primary endpoint of the intervention is the composite variable necrotizing enterocolitis (NEC), sepsis and mortality.

The enrolled infants are characterised with clinical data including growth, feeding intolerance, use of enteral and parenteral nutrition, treatment, antibiotics and complications collected daily in a study specific case report form from birth until discharge from the hospital (not longer than gestational week 44+0). A follow up focusing on neurological development, growth and feeding problems will be performed at 2 years of age (corrected) and 5.5 years of age.

The 2 groups in the trial

  • H2MFTreatment being tested

    Human milk-based breast milk fortifier

  • Standard fortifierExisting treatment, for comparison

    Standard care: bovine milk-based breast milk fortifier

    Treatment: Bovine milk-based fortifier

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Nordic Study on Human Milk Fortification in Extremely Preterm Infants: a Randomized Controlled Trial
Publications
Record updated
23 July 2024